Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4849-53. doi: 10.1016/j.bmcl.2012.05.034. Epub 2012 May 15.

Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.

Author information

1
Theravance, Inc., 901 Gateway Blvd, South San Francisco, CA 94080, USA. dlong@theravance.com

Abstract

Further application of our multivalent approach to drug discovery directed to 5-HT(4) receptor agonists is described. Optimization of the linker and secondary binding amine in the indazole-tropane primary binding group series, for binding affinity and functional potency at the 5-HT(4) receptor, selectivity over the 5-HT(3) receptor, oral pharmacokinetics, and in vivo efficacy in models of GI motility, resulted in the identification of clinical compound TD-2749.

PMID:
22683222
DOI:
10.1016/j.bmcl.2012.05.034
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center